Simvastatin is a substrate of cytochrome P450 3A4, and a consequence of its coadministration with potent inhibitors of cytochrome P450 3A4 is the increase in the concentration of the drug in the plasma and risk of myopathy and rhabdomyolysis [39]. This evidence concerns the gene CYP3A4 and rhabdomyolysis.